Matches in Wikidata for { <http://www.wikidata.org/entity/Q91486072> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q91486072 description "article scientifique publié en 2019" @default.
- Q91486072 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91486072 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91486072 description "scientific article published on 27 November 2019" @default.
- Q91486072 description "wetenschappelijk artikel" @default.
- Q91486072 description "наукова стаття, опублікована 27 листопада 2019" @default.
- Q91486072 name "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 name "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 type Item @default.
- Q91486072 label "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 label "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 prefLabel "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 prefLabel "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 P1433 Q91486072-F8057E5B-9A33-477A-AB00-5B86E5A197BA @default.
- Q91486072 P1476 Q91486072-55E83E26-8407-4608-8AFB-0FC5BFCF3C23 @default.
- Q91486072 P2093 Q91486072-156FB324-4769-406C-BB58-66B9622313A7 @default.
- Q91486072 P2093 Q91486072-329E0444-5305-44E5-8414-3C7AB21BC2EB @default.
- Q91486072 P2093 Q91486072-35F4E31B-9BD1-4243-BC3B-1B86297E6AD1 @default.
- Q91486072 P2093 Q91486072-5A096C14-2159-4613-9460-B1B8FE506299 @default.
- Q91486072 P2093 Q91486072-CC479FF3-11C8-42C1-9BBB-7335DA3829E8 @default.
- Q91486072 P2093 Q91486072-E3F4435F-E114-4FAE-9742-465E1D48E3CB @default.
- Q91486072 P304 Q91486072-D2BD2F05-134A-4F7E-ACA2-370FA297598D @default.
- Q91486072 P31 Q91486072-5426C626-FE3F-414F-B87D-ECBDF2EF7BB2 @default.
- Q91486072 P356 Q91486072-23F12EB9-FBC2-41BE-A0D0-B42DB134D924 @default.
- Q91486072 P433 Q91486072-73454DA0-AF17-4DFC-A551-6B7ECC821F39 @default.
- Q91486072 P478 Q91486072-552DB060-859F-4840-B24C-5E9D6EDDEBCA @default.
- Q91486072 P577 Q91486072-0F709DD6-4078-41EC-8CC0-C512FD419F38 @default.
- Q91486072 P698 Q91486072-8425AE0E-C173-4E38-8BA9-46EC93D965FB @default.
- Q91486072 P921 Q91486072-B66EDD51-0F76-4BFD-B95F-F6FD7CF25A77 @default.
- Q91486072 P921 Q91486072-F8CDC6A2-4D14-45AB-8E7B-FCC274E2DAA8 @default.
- Q91486072 P356 IMT-2019-0177 @default.
- Q91486072 P698 31774363 @default.
- Q91486072 P1433 Q18713038 @default.
- Q91486072 P1476 "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices" @default.
- Q91486072 P2093 "Bilal Piperdi" @default.
- Q91486072 P2093 "M Catherine Pietanza" @default.
- Q91486072 P2093 "Sheenu Chandwani" @default.
- Q91486072 P2093 "Thomas Burke" @default.
- Q91486072 P2093 "Vamsidhar Velcheti" @default.
- Q91486072 P2093 "Xin Chen" @default.
- Q91486072 P304 "1541-1554" @default.
- Q91486072 P31 Q13442814 @default.
- Q91486072 P356 "10.2217/IMT-2019-0177" @default.
- Q91486072 P433 "18" @default.
- Q91486072 P478 "11" @default.
- Q91486072 P577 "2019-11-27T00:00:00Z" @default.
- Q91486072 P698 "31774363" @default.
- Q91486072 P921 Q13896859 @default.
- Q91486072 P921 Q3658562 @default.